Table 1 Comparison of baseline data and 24-week anti-HBs levels
Vaccine group (n = 14) | Non-vaccine group (n = 14) | p value | |
|---|---|---|---|
Sex, Male, n (%) Female, n (%) | 8 (57.1%) 6 (41.9%) | 8 (57.1%) 6 (41.9%) | 1 |
Age, years Range | 35.64 ± 7.49 26–51 | 37.29 ± 13.19 27–55 | 0.688 |
ALT at baseline (U/L) | 19.64 ± 5.94 | 16.64 ± 5.31 | 0.171 |
Anti-HBs positive conversion (≥ 10 IU/L) rate at week 24 | 100% (14) | 50% (7) | 0.006 |
Median of Anti-HBs at week 24, IU/L | 409.3 | 8.97 | 0.007 |
Proportion of anti-HBs ≥ 100 IU/L at week 24, % (n) | 64.3% (9) | 21.4% (3) | 0.022 |
Proportion of anti-HBs ≥ 300 IU/L at week 24, % (n) | 57.1% (8) | 14.3% (2) | 0.018 |